2023-04-04 16:37:31 ET
- Thorne HealthTech ( THRN ) on Tuesday announced significant positive findings from a placebo-controlled trial testing SynaQuell, a multi-ingredient nutritional supplement that supports healthy brain structure.
- The trial, which was done in collaboration with Mayo Clinic and HealthTech Connex, measured brain function in ice hockey players over a season.
- The participants went through baseline brain function testing at the beginning of the season, then took either Thorne's SynaQuell or a placebo daily for the duration of the season.
- The study found - those with and without a history of prior concussions – there were significant positive changes when comparing the SynaQuell group to the placebo group.
- There were positive changes in brainwave latency specific selective attention and focus ( N100 ) and Visual processing speed tests.
- "The evidence obtained and the analysis performed in this trial is mission critical to the truly massive potential that SynaQuell has as it relates to supporting healthy brain function across a wide range of individuals, including athletes across various levels and ages, the military, children, and more," the company said.
- Press Release
For further details see:
Thorne posts positive data from brain nutritional supplement trial